{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:17:53Z","timestamp":1784819873560,"version":"3.55.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The high prevalence and severe complications of type 2 diabetes mellitus (T2DM) pose significant threats to public health systems worldwide. An in-depth understanding of T2DM pathophysiology has brought focused attention to pharmacological strategies for achieving disease remission. However, limited knowledge exists regarding their efficacy, patient stratification strategies, and long-term effects. By constructing an analytical framework integrating \u201cmechanism-drug-strategies,\u201d we explore mechanisms of action and clinical effects of multiple medications (insulin, metformin, sodium\u2013glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) for T2DM remission and analyze synergistic effects of combination therapies. Short-term intensive insulin therapy significantly improves \u03b2-cell function and insulin sensitivity, resulting in sustained glycemic remission in certain patients. Novel multi-target drugs (GLP-1\/gastric inhibitory polypeptide dual agonists) demonstrate significant glycemic control and weight loss advantages. Non-antihyperglycemic drugs (vitamin D, sex hormones) demonstrate diabetes remission potential. Combined therapies (insulin with oral hypoglycemic agents, multitarget oral drug combinations) improve remission rates and prolong remission duration. This study systematically synthesized evidence on the multidimensional progress in pharmacological interventions for T2DM remission to support clinical practice and promote the transition of T2DM remission from a theoretical concept to individualized clinical application. Through an in-depth analysis of drug mechanisms of action and clinical research, new perspectives and strategies for optimizing treatment plans, improving diabetes remission rates, and reducing medication burdens, potentially providing important references for global T2DM management, are described. Future research focusing on long-acting combination strategies, predictive model construction, and translational medicine validation may cause a paradigm shift, from \u201cglycemic control\u201d to \u201cdisease remission.\u201d<\/jats:p>","DOI":"10.3389\/fendo.2025.1687601","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:12Z","timestamp":1764911592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12791","article-title":"Current prevalence of type 1 and type 2 diabetes in adults and children in the UK","volume":"32","author":"Holman","year":"2015","journal-title":"Diabet. Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e200087","DOI":"10.1001\/jamasurg.2020.0087","article-title":"Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the national patient-centered clinical research network (PCORNet) bariatric study","volume":"155","author":"McTigue","year":"2020","journal-title":"JAMA Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00129-X","article-title":"Metabolic surgery versus conventional therapy in type 2 diabetes","volume":"397","author":"Miras","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30117-0","article-title":"Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial","volume":"8","author":"Taheri","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e64009","DOI":"10.1371\/journal.pone.0064009","article-title":"Making and maintaining lifestyle changes after participating in group based type 2 diabetes self-management educations: a qualitative study","volume":"8","author":"Rise","year":"2013","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0034","article-title":"Consensus report: definition and interpretation of remission in type 2 diabetes","volume":"44","author":"Riddle","year":"2021","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1375","article-title":"A glycemic threshold above which the improvement of \u03b2-cell function and glycemia in response to insulin therapy is amplified in early type 2 diabetes: the reversal of glucotoxicity","volume":"47","author":"Retnakaran","year":"2024","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dbi19-0014","article-title":"Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic \u03b2-cell","volume":"69","author":"Prentki","year":"2020","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/db16-1213","article-title":"Pair feeding, but not insulin, phloridzin, or rosiglitazone treatment, curtails markers of \u03b2-cell dedifferentiation in db\/db mice","volume":"66","author":"Ishida","year":"2017","journal-title":"Diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0619","article-title":"Type 2 diabetes: the pathologic basis of reversible \u03b2-cell dysfunction","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1437","DOI":"10.1002\/ctm2.1437","article-title":"Plasma extrachromosomal circular DNA is a pathophysiological hallmark of short-term intensive insulin therapy for type 2 diabetes","volume":"13","author":"Xu","year":"2023","journal-title":"Clin Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e080122","DOI":"10.1136\/bmj-2024-080122","article-title":"Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial","volume":"387","author":"Liu","year":"2024","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2105","article-title":"Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and \u03b2-cell function in subjects with long-term remission","volume":"34","author":"Hu","year":"2011","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01468","article-title":"Predictors of long-term glycemic remission after 2-week intensive insulin treatment in newly diagnosed type 2 diabetes","volume":"104","author":"Wang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e19685","DOI":"10.1097\/MD.0000000000019685","article-title":"Effect of short-term intensive insulin therapy on \u03b1-cell function in patients with newly diagnosed type 2 diabetes","volume":"99","author":"Zheng","year":"2020","journal-title":"Med (Baltim.)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12813","article-title":"Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes","volume":"9","author":"Hirukawa","year":"2018","journal-title":"J Diabetes Investig"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.02.027","article-title":"Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)","volume":"66","author":"Jia","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15234","article-title":"Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine\/lixisenatide, metformin and lifestyle approaches: results of a randomised controlled trial","volume":"25","author":"McInnes","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once Weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa248","article-title":"Remission of type 2 diabetes following a short-term intervention with insulin glargine, metformin, and dapagliflozin","volume":"105","author":"McInnes","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled tria","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/cd18-0105","article-title":"Standards of medical care in Diabetes-2019 abridged for primary care providers","volume":"37","year":"2019","journal-title":"Clin Diabetes"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in cancer treatment and prevention","volume":"66","author":"Morales","year":"2015","journal-title":"Annu Rev Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.arr.2018.10.003","article-title":"Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing","volume":"48","author":"Prattichizzo","year":"2018","journal-title":"Ageing Res Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0406","article-title":"Randomized controlled study of metformin and sitagliptin on long-term normoglycemia remission in African American patients with hyperglycemic crises","volume":"39","author":"Vellanki","year":"2016","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":". Diabetes"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.12.020","article-title":"Thiazolidinediones and PPAR orchestra as antidiabetic agents: from past to present","volume":"126","author":"Yasmin","year":"2017","journal-title":"Eur J Med Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000217","article-title":"Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances","volume":"23","author":"Gallwitz","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2021","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1038\/s41467-022-33867-9","article-title":"The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial","volume":"13","author":"Retnakaran","year":"2022","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1038\/s41598-017-02631-1","article-title":"Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial","volume":"7","author":"Shi","year":"2017","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide Once Weekly in Patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014A Phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1292","article-title":"Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on \u03b2-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes","volume":"28","author":"Mu","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3373","article-title":"Piloting a remission strategy in type 2 diabetes: results of a randomized controlled trial","volume":"102","author":"McInnes","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0278","article-title":"Remission of type 2 diabetes following a short-term intensive intervention with insulin glargine, sitagliptin, and metformin: results of an open-label randomized parallel-design trial","volume":"45","author":"McInnes","year":"2022","journal-title":"Diabetes Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0013","article-title":"Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant \u03b1-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus","volume":"15","author":"Huang","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12417","article-title":"Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Metab"},{"key":"B59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1124\/pr.117.014373","article-title":"G protein-coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus","volume":"70","author":"Riddy","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00892","article-title":"The discovery, preclinical, and early clinical development of potent and selective GPR40 agonists for the treatment of type 2 diabetes mellitus (LY2881835, LY2922083, and LY2922470)","volume":"59","author":"Hamdouchi","year":"2016","journal-title":"J Med Chem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01525.x","article-title":"GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes","volume":"14","author":"Araki","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0872","article-title":"Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes","volume":"36","author":"Kaku","year":"2013","journal-title":"Diabetes Care"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2337\/db25-0096","article-title":"A randomized controlled, double-masked, crossover study of a GPR119 agonist on glucagon counterregulation during hypoglycemia in type 1 diabetes","volume":"74","author":"Bilal","year":"2025","journal-title":"Diabetes"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2019.100206","article-title":"Type 2 diabetes mellitus non-surgical remission: A possible mission","volume":"18","author":"Allam","year":"2019","journal-title":"J Clin Transl Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1003828","DOI":"10.1371\/journal.pmed.1003828","article-title":"Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional population-based study","volume":"18","author":"Captieux","year":"2021","journal-title":"PloS Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.67929","article-title":"Association of an intensive lifestyle intervention with remission of type 2 diabetes","volume":"308","author":"Gregg","year":"2012","journal-title":"JAMA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e000652","DOI":"10.20945\/2359-3997000000652","article-title":"Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study","volume":"67","author":"Pinheiro","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2064","article-title":"Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial","volume":"329","author":"Forlenza","year":"2023","journal-title":"JAMA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/01.hjh.0000357903.93951.73","article-title":"Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension","volume":"27","author":"Weber","year":"2009","journal-title":"J Hypertens"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2388","article-title":"Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study","volume":"42","author":"Yassin","year":"2019","journal-title":"Diabetes Care"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15040242","article-title":"Metabolic changes in patients with premature ovarian insufficiency: adipose tissue focus-A narrative review","volume":"15","author":"S\u00e1nchez-Garc\u00eda","year":"2025","journal-title":"Metabolites"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.190676","article-title":"Effect of Chinese herbal medicine Jinlida granule in treatment of patients with impaired glucose tolerance","volume":"129","author":"Shi","year":"2016","journal-title":"Chin Med J (Engl.)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3276","article-title":"Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial","volume":"99","author":"Lian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obes (Silver Spring)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2016.1201853","article-title":"Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects","volume":"48","author":"Jorde","year":"2016","journal-title":"Infect Dis (Lond.)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15941","article-title":"Efficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: an updated systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Chen","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-020-02419-6","article-title":"Glycemic control improvement in individuals with type 2 diabetes with vitamin K2 supplementation: a randomized controlled trial","volume":"60","author":"Rahimi Sakak","year":"2021","journal-title":"Eur J Nutr"},{"key":"B82","article-title":"The effect of quercetin supplementation on oxidative stress, glycemic control, lipid profile and insulin resistance in type 2 diabetes: A randomized clinical trial","volume":"2","author":"Mazloom","year":"2014","journal-title":"J Health Sci Surveill Syst"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"B84","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: a systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1041505","article-title":"Combination phentermine and topiramate extended release in the management of obesity","volume":"16","author":"Alfaris","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"B86","article-title":"Naltrexone\/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults","volume":"41","author":"Sherman","year":"2016","journal-title":"P T"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01920-6","article-title":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis","volume":"398","author":"Nazarzadeh","year":"2021","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12986-021-00597-6","article-title":"Calcium channel blockers do not protect against saturated fatty acid-induced ER stress and apoptosis in human pancreatic \u03b2-cells","volume":"18","author":"\u0160r\u00e1mek","year":"2021","journal-title":"Nutr Metab (Lond.)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i4.536","article-title":"Novel treatment approaches in hypertensive type 2 diabetic patients","volume":"5","author":"Castro Torres","year":"2014","journal-title":"World J Diabetes"},{"key":"B90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/dc15-1518","article-title":"Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes","volume":"39","author":"Dhindsa","year":"2016","journal-title":"Diabetes Care"},{"key":"B91","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/EJE-15-0262","article-title":"THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study","volume":"174","author":"Corona","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14206","article-title":"Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review","volume":"23","author":"Dandona","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13367","article-title":"Testosterone therapy in diabetes and pre-diabetes","volume":"11","author":"Corona","year":"2023","journal-title":"Andrology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2021.04.002","article-title":"Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone","volume":"58","author":"Caliber","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0451","article-title":"Effect of postmenopausal hormone therapy on glucose regulation in women with Type 1 or type 2 diabetes: A systematic review and meta-analysis","volume":"46","author":"Speksnijder","year":"2023","journal-title":"Diabetes Care"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2017.11.019","article-title":"Coriander (Coriandrum sativum): A promising functional food toward the well-being","volume":"105","author":"Prachayasittikul","year":"2018","journal-title":"Food Res Int"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6465","article-title":"Aloe vera as an herbal medicine in the treatment of metabolic syndrome: a review","volume":"33","author":"Shakib","year":"2019","journal-title":"Phytother. Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9340637","article-title":"Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes","volume":"2016","author":"Chen","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2012.01.019","article-title":"Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits","volume":"29","author":"Bhaskar","year":"2013","journal-title":"Nutrition"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.70.933","article-title":"Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet","volume":"70","author":"Yamamoto","year":"2006","journal-title":"Biosci Biotechnol Biochem"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-018-1713-2","article-title":"Estimated daily quercetin intake and association with the prevalence of type 2 diabetes mellitus in Chinese adults","volume":"58","author":"Yao","year":"2019","journal-title":"Eur J Nutr"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/nure.12091","article-title":"Seaweed and human health","volume":"72","author":"Brown","year":"2014","journal-title":"Nutr Rev"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/md13042196","article-title":"Anti-obesity activity of the marine carotenoid fucoxanthin","volume":"13","author":"Gammone","year":"2015","journal-title":"Mar Drugs"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.18.1.147","article-title":"Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells","volume":"18","author":"Maeda","year":"2006","journal-title":"Int J Mol Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/md13084799","article-title":"Fucoxanthinol, Metabolite of Fucoxanthin, improves obesity-induced inflammation in adipocyte cells","volume":"13","author":"Maeda","year":"2015","journal-title":"Mar Drugs"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2008.06.013","article-title":"Daily ingestion of alginate reduces energy intake in free-living subjects","volume":"51","author":"Paxman","year":"2008","journal-title":"Appetite"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.7570\/jomes.2018.27.4.223","article-title":"Vitamin D and metabolic diseases: growing roles of vitamin D","volume":"27","author":"Park","year":"2018","journal-title":"J Obes Metab Syndr"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1039\/d0fo03230a","article-title":"Molecular mechanisms from insulin-mimetic effect of vitamin D: treatment alternative in type 2 diabetes mellitus","volume":"12","author":"Torres Dominguez","year":"2021","journal-title":"Food Funct"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900906","article-title":"Vitamin D supplementation and prevention of type 2 diabetes","volume":"381","author":"Pittas","year":"2019","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e066222","DOI":"10.1136\/bmj-2021-066222","article-title":"Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population","volume":"377","author":"Kawahara","year":"2022","journal-title":"BMJ"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3018","article-title":"Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials","volume":"176","author":"Pittas","year":"2023","journal-title":"Ann Intern Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2472","article-title":"Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study","volume":"98","author":"D\u00edaz-L\u00f3pez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B113","doi-asserted-by":"publisher","first-page":"39\u201451","DOI":"10.1016\/j.diabres.2017.11.020","article-title":"Effect of vitamin K2 on type 2 diabetes mellitus: a review","volume":"136","author":"Li","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2302","article-title":"Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes","volume":"33","author":"Beulens","year":"2010","journal-title":"Diabetes Care"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.033498","article-title":"Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease","volume":"96","author":"Ibarrola-Jurado","year":"2012","journal-title":"Am J Clin Nutr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1687601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:14Z","timestamp":1764911594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1687601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":115,"alternative-id":["10.3389\/fendo.2025.1687601"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1687601","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1687601"}}